The Lancet Oncology最新文献

{"title":"Dural metastasis of prostate cancer resembling meningioma","authors":"Chao Wei, Wei Wei","doi":"10.1016/s1470-2045(25)00073-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00073-7","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>CW conceived the project and drafted the manuscript. WW revised the draft. Both authors approved the final manuscript. Written informed consent to publication was obtained from the patient.</section></section><section><section><h2>Declaration of interests</h2>We declare no competing interests.</section></section>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer–WHO Regional Office for the Eastern Mediterranean collaboration","authors":"Ariana Znaor, Heba Fouad, Mariam Zahwe, Sultan Eser, Ibtihal Fadhil, Isabelle Soerjomataram, Asmus Hammerich, Freddie Bray","doi":"10.1016/s1470-2045(24)00624-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00624-7","url":null,"abstract":"The Eastern Mediterranean region covers a population of more than 700 million individuals and 22 countries and territories, sharing histories, culture, and languages. The countries and territories of this region also have large differences in demographics and human development. Population ageing and growth is predicted to more than double the number of new cancer cases in the region over the next few decades, from 782 000 in 2022 to close to 1·8 million by the year 2050. At the same time, cancer control capacity is low, with large inequalities between and within countries, further aggravated by political instability and conflicts. From 2013, the International Agency for Research on Cancer and the WHO Regional Office for the Eastern Mediterranean have been working together to strengthen cancer surveillance to inform regional and national cancer control. Based on an exposition of the cancer patterns, this Policy Review summarises remaining opportunities and barriers in ensuring high-quality cancer surveillance in all WHO Eastern Mediterranean countries and territories.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2024; 25: 1424–39","authors":"","doi":"10.1016/s1470-2045(25)00036-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00036-1","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining multimodal strategies for locally advanced NSCLC","authors":"Zaoqu Liu, Long Liu, Dan Shan, Xinwei Han","doi":"10.1016/s1470-2045(25)00038-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00038-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation","authors":"Zachary S Morris, Sandra Demaria, Arta M Monjazeb, Silvia C Formenti, Ralph R Weichselbaum, James Welsh, Heiko Enderling, Jonathan D Schoenfeld, Joshua D Brody, Heather M McGee, Michele Mondini, Michael S Kent, Kristina H Young, Lorenzo Galluzzi, Sana D Karam, Willemijn S M E Theelen, Joe Y Chang, Mai Anh Huynh, Adi Daib, Sean Pitroda, Lawrence Fong","doi":"10.1016/s1470-2045(24)00656-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00656-9","url":null,"abstract":"Radiotherapy both promotes and antagonises tumour immune recognition. Some clinical studies show improved patient outcomes when immunotherapies are integrated with radiotherapy. Safe, greater than additive, clinical response to the combination is limited to a subset of patients, however, and how radiotherapy can best be combined with immunotherapies remains unclear. The National Cancer Institute–Immuno-Oncology Translational Network–Society for Immunotherapy of Cancer–American Association of Immunology Workshop on Combining Immunotherapy with Radiotherapy was convened to identify and prioritise opportunities and challenges for radiotherapy and immunotherapy combinations. Sessions examined the immune effects of radiation, barriers to anti-tumour immune response, previous clinical trial data, immunological and computational assessment of response, and next-generation radiotherapy–immunotherapy combinations. Panel recommendations included: developing and implementing patient selection and biomarker-guided approaches; applying mechanistic understanding to optimise delivery of radiotherapy and selection of immunotherapies; using rigorous preclinical models including companion animal studies; embracing data sharing and standardisation, advanced modelling, and multidisciplinary cross-institution collaboration; interrogating clinical data, including negative trials; and incorporating novel clinical endpoints and trial designs.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose optimisation to improve access to effective cancer medicines","authors":"Ian F Tannock, Elisabeth G E de Vries, Antonio Fojo, Marc Buyse, Lorenzo Moja","doi":"10.1016/s1470-2045(24)00648-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00648-x","url":null,"abstract":"Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted because of price, especially in low-income and middle-income countries (LMICs). Other cancer medicines that have been shown to improve survival, such as immune checkpoint inhibitors for lung cancer, are not included on the EML because approved doses and schedules exceed affordable prices in LMICs. Multiple strategies are therefore needed to reduce medicine costs or circumvent these problems, such as optimising doses and schedules. Cancer medicines are approved by regulatory agencies, such as the US Food and Drug Administration and the European Medicines Agency, following rigorous clinical trials. However, these approvals can involve dosing regimens and treatment schedules that, although effective in showing statistically significant benefits in trials, can be higher in intensity, frequency, or duration than is necessary to achieve meaningful improved survival. In clinical practice, these regimens can lead to concerns about balancing optimal therapeutic outcomes with the risk of side-effects, patient quality of life, and long-term health effects. Various types of evidence can, and should, be used to explore and show near-equivalence of beneficial outcomes from reduced-intensity treatments, including randomised clinical trials, dose-finding phase 1 and 2 studies, and pharmacokinetic and pharmacodynamic studies. The positive effects of proving that lower doses or less intensive schedules retain therapeutic activity include reduced toxicity and large price reductions, leading to better cost-effectiveness and greater access to treatments that improve survival. Beyond regulatory approvals, identification of regimens that have similar outcomes with reduced doses and less intense schedules should be a priority for clinicians and policy makers in the selection process to identify effective medicines at national and global levels.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining multimodal strategies for locally advanced NSCLC – Authors' reply","authors":"John H Heinzerling, Kathryn F Mileham, Myra M Robinson, Charles B Simone","doi":"10.1016/s1470-2045(25)00086-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00086-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionising cancer treatment access in low-income and middle-income countries: a sustainable approach","authors":"Amy Israel, Cary Adams, Gilberto Lopes, Dan Milner, Sumithra Krishnamurthy Reddiar","doi":"10.1016/s1470-2045(25)00071-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00071-3","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"211 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer care in SAARC countries","authors":"Maihan Abdullah","doi":"10.1016/s1470-2045(25)00067-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00067-1","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer survivor-led patient advocacy: the ICanServe experience from the Philippines","authors":"Maria Jocelyn Kara Magsanoc-Alikpala, Aveline Marie D Ylanan, Cecilia Rivera-Montales, Juan Martin Magsanoc, Michelle Ann B Eala, Edward Christopher Dee","doi":"10.1016/s1470-2045(24)00632-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00632-6","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Ating Dibdibin: a programme for Filipinos with breast cancer</h2>Founded and led primarily by survivors of breast cancer, ICanServe established a programme called Ating Dibdibin (Take Your Breast Care to Heart). Long before the enactment of the NICCA and release of WHO's Global Breast Cancer Initiative (GBCI), the programme has been in place since 2008 to promote prevention, early diagnosis, and timely access to treatment; to provide supportive and survivorship care; and to implement patient navigation to improve adherence. In the setting of the</section></section><section><section><h2>Ating Dibdibin: community outcomes</h2>Ating Dibdibin has been adopted by seven cities (Marikina City, Panabo City, Tagum City, San Juan City, Muntinlupa City, Taguig City, and Baguio City). In the city of Taguig, in which the Ating Dibdibin programme started in 2011, almost 200 000 women have attended lectures or forums, and more than 125 000 have been screened via clinical breast examination. Additionally, almost 6000 patients have had relevant findings on clinical breast examination and have subsequently undergone diagnostic</section></section><section><section><section><h2>Empower the target group and understand their needs</h2>As a survivor-led organisation, ICanServe understands the challenges and needs of Filipino patients with breast cancer. Financial toxicity at each level of the cancer continuum is a substantial barrier. ICanServe addresses financial toxicity by empowering both patients and local governments to access already available funding sources such as the Gender and Development Fund, which mandates a 10% allocation from government budgets for programmes such as Ating Dibdibin. Additionally, the programme</section></section></section><section><section><h2>Conclusion</h2>Ating Dibdibin can be a springboard to establish a breast cancer control programme that can branch out to other types of cancer. Other local government partners have used the same programme principles of the Ating Dibdibin programme for cervical cancer control.ICanServe's Ating Dibdibin programme offers valuable insights for countries facing similar challenges in breast cancer control, showing that patient-led efforts are not only viable but successful in low-income and middle-income settings.</section></section>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"12 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}